HK Stock Movement | REMEGEN (09995) Rises Over 3% as Self-Developed RC148 Achieves Dual-Path Breakthrough; Institutions Bullish on Clinical Potential

Stock News10:06

REMEGEN (09995) surged over 3%, reaching HK$78.8 by the time of writing, with a trading volume of HK$98.38 million. According to a research report, the company's self-developed PD-1/VEGF bispecific antibody RC148 has demonstrated promising results in Phase I/II clinical trials for first-line monotherapy and second-line combination therapy in non-small cell lung cancer (NSCLC). Data revealed that RC148 exhibited significant clinical efficacy and manageable safety in both monotherapy and combination approaches, marking a dual-path breakthrough.

Based on early data from the RC148-C001 study, RC148, in combination with docetaxel, received Breakthrough Therapy Designation (BTD) in China in August 2025 for treating driver gene-negative locally advanced or metastatic NSCLC patients who failed prior PD-1/PD-L1 inhibitor and platinum-based chemotherapy (sequential or concurrent). The company is actively advancing related clinical trials: according to investor updates, patient enrollment for the Phase II trial of RC148 combination therapy in first-line NSCLC has been completed, with plans to initiate a Phase III study. Institutions remain optimistic about its future clinical potential.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1105874842?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-12-23 10:06","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1105874842","market":"fut","top_or_hot":-1,"title":"HK Stock Movement | REMEGEN (09995) Rises Over 3% as Self-Developed RC148 Achieves Dual-Path Breakthrough; Institutions Bullish on Clinical Potential","media":"Stock News","content":"<p>REMEGEN (09995) surged over 3%, reaching HK$78.8 by the time of writing, with a trading volume of HK$98.38 million. According to a research report, the company's self-developed PD-1/VEGF bispecific antibody RC148 has demonstrated promising results in Phase I/II clinical trials for first-line monotherapy and second-line combination therapy in non-small cell lung cancer (NSCLC). Data revealed that RC148 exhibited significant clinical efficacy and manageable safety in both monotherapy and combination approaches, marking a dual-path breakthrough.</p>\n<p>Based on early data from the RC148-C001 study, RC148, in combination with docetaxel, received Breakthrough Therapy Designation (BTD) in China in August 2025 for treating driver gene-negative locally advanced or metastatic NSCLC patients who failed prior PD-1/PD-L1 inhibitor and platinum-based chemotherapy (sequential or concurrent). The company is actively advancing related clinical trials: according to investor updates, patient enrollment for the Phase II trial of RC148 combination therapy in first-line NSCLC has been completed, with plans to initiate a Phase III study. Institutions remain optimistic about its future clinical potential.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>HK Stock Movement | REMEGEN (09995) Rises Over 3% as Self-Developed RC148 Achieves Dual-Path Breakthrough; Institutions Bullish on Clinical Potential</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHK Stock Movement | REMEGEN (09995) Rises Over 3% as Self-Developed RC148 Achieves Dual-Path Breakthrough; Institutions Bullish on Clinical Potential\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2025-12-23 10:06</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>REMEGEN (09995) surged over 3%, reaching HK$78.8 by the time of writing, with a trading volume of HK$98.38 million. According to a research report, the company's self-developed PD-1/VEGF bispecific antibody RC148 has demonstrated promising results in Phase I/II clinical trials for first-line monotherapy and second-line combination therapy in non-small cell lung cancer (NSCLC). Data revealed that RC148 exhibited significant clinical efficacy and manageable safety in both monotherapy and combination approaches, marking a dual-path breakthrough.</p>\n<p>Based on early data from the RC148-C001 study, RC148, in combination with docetaxel, received Breakthrough Therapy Designation (BTD) in China in August 2025 for treating driver gene-negative locally advanced or metastatic NSCLC patients who failed prior PD-1/PD-L1 inhibitor and platinum-based chemotherapy (sequential or concurrent). The company is actively advancing related clinical trials: according to investor updates, patient enrollment for the Phase II trial of RC148 combination therapy in first-line NSCLC has been completed, with plans to initiate a Phase III study. Institutions remain optimistic about its future clinical potential.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"688331","symbol_name":"荣昌生物","start_time":0,"source_url":"","article_id":"1105874842","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1105874842","pubTimestamp":1766455574,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"REMEGEN (09995) surged over 3%, reaching HK$78.8 by the time of writing, with a trading volume of HK$98.38 million. According to a research report, the company's self-developed PD-1/VEGF bispecific...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"688331":"荣昌生物","BK1574":"生物医药B类股","BK1583":"高瓴概念","LU1064130708.USD":"FULLERTON LUX FUNDS - CHINA A EQUITIES \"I\" (USD) ACC","LU2148510915.USD":"FULLERTON LUX FUNDS - CHINA A EQUITIES \"R\" (USD) ACC","LU2328871848.SGD":"Eastspring Investments - China A Shares Growth AS SGD","LU1969619763.USD":"EASTSPRING INV CHINA A SHARES GROWTH \"A\" (USD) ACC","BK0239":"医药制造","LU2488822045.USD":"ALLIANZ CHINA HEALTHY LIVING \"AT\" (USD) ACC","LU1064131003.USD":"FULLERTON LUX FUNDS - CHINA A EQUITIES \"A\" (USD) ACC","09995":"荣昌生物","BK1161":"生物科技"},"translate_title":"港股动向|瑞美根(09995)涨超3%，自研RC148实现双路径突破；机构看好临床潜力","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"688331":1,"09995":1},"content_text":"REMEGEN (09995) surged over 3%, reaching HK$78.8 by the time of writing, with a trading volume of HK$98.38 million. According to a research report, the company's self-developed PD-1/VEGF bispecific antibody RC148 has demonstrated promising results in Phase I/II clinical trials for first-line monotherapy and second-line combination therapy in non-small cell lung cancer (NSCLC). Data revealed that RC148 exhibited significant clinical efficacy and manageable safety in both monotherapy and combination approaches, marking a dual-path breakthrough.\nBased on early data from the RC148-C001 study, RC148, in combination with docetaxel, received Breakthrough Therapy Designation (BTD) in China in August 2025 for treating driver gene-negative locally advanced or metastatic NSCLC patients who failed prior PD-1/PD-L1 inhibitor and platinum-based chemotherapy (sequential or concurrent). The company is actively advancing related clinical trials: according to investor updates, patient enrollment for the Phase II trial of RC148 combination therapy in first-line NSCLC has been completed, with plans to initiate a Phase III study. Institutions remain optimistic about its future clinical potential.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1105874842","isCrawlerRequest":true}